Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Therapy Is Safe and Facilitates Treatment-free Intervals

Patients with metastatic renal cell cancer (mRCC) who respond to upfront immune checkpoint inhibitor (ICI) combination therapies may be treated with cytoreductive nephrectomy (CN) to remove radiographically viable primary tumors. Early data for post-ICI CN suggested that ICI therapies induce desmopl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shapiro, Daniel D., Karam, Jose A., Zemp, Logan, Master, Viraj A., Sexton, Wade J., Ghasemzadeh, Ali, Schmeusser, Benjamin N., Davaro, Facundo, Peak, Taylor, Patil, Dattatraya, Matin, Surena, Spiess, Philippe E., Abel, E. Jason
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Brief Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969293/
https://www.ncbi.nlm.nih.gov/pubmed/36861106
http://dx.doi.org/10.1016/j.euros.2023.01.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9969293/
https://www.ncbi.nlm.nih.gov/pubmed/36861106
http://dx.doi.org/10.1016/j.euros.2023.01.016

Ejemplares similares